$MBIO
MUSTANG BIO, INC. Stock $mbio

$mbio Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000114420418059357 Filed on November 13, 2018

Income Statement

Concept	2018 Q3	2017 Q4	2017 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.340M	$3.120M	$4.600M
YoY Change	-70.87%	212.0%	318.18%
% of Gross Profit
Research & Development	$5.316M	$12.61M	$500.0K
YoY Change	963.2%	84.63%	0.0%
% of Gross Profit
Depreciation & Amortization	$200.0K	$0.00	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$7.656M	$15.73M	$7.084M
YoY Change	8.07%	100.89%	324.19%
Operating Profit	-$7.656M	-$15.73M	-$7.084M
YoY Change	8.07%	100.87%	324.19%
Interest Expense	$140.0K	$130.0K	$140.0K
YoY Change	0.0%	-114.13%	-170.0%
% of Operating Profit
Other Income/Expense, Net	$138.0K	$129.0K	$144.0K
YoY Change	-4.17%	-114.07%	-172.0%
Pretax Income	-$7.520M	-$15.60M	-$6.940M
YoY Change	8.36%	78.29%	271.12%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$7.518M	-$15.60M	-$6.940M
YoY Change	8.33%	78.34%	271.12%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$277.0K	-$595.4K	-$265.0K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2017 Q4	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$40.80M	$61.00M	$67.30M
YoY Change	-39.38%	121.82%	506.31%
Cash & Equivalents	$18.80M	$35.48M	$33.21M
Short-Term Investments	$22.50M	$26.00M	$34.10M
Other Short-Term Assets	$900.0K	$300.0K	$400.0K
YoY Change	125.0%
Inventory
Prepaid Expenses	$872.0K	$278.0K	$414.0K
Receivables
Other Receivables	$50.00K	$0.00
Total Short-Term Assets	$41.83M	$61.36M	$67.75M
YoY Change	-38.26%	123.14%	509.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.793M	$1.381M	$139.0K
YoY Change	4787.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$394.0K	$251.0K
YoY Change
Total Long-Term Assets	$7.687M	$2.132M	$139.0K
YoY Change	5430.22%
TOTAL ASSETS
Total Short-Term Assets	$41.83M	$61.36M	$67.75M
Total Long-Term Assets	$7.687M	$2.132M	$139.0K
Total Assets	$49.51M	$63.49M	$67.89M
YoY Change	-27.06%	130.89%	510.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.100M	$3.600M	$2.800M
YoY Change	46.43%	414.29%	180.0%
Accrued Expenses	$300.0K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.052M	$3.611M	$2.800M
YoY Change	44.71%	12.04%	-42.49%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$500.0K	$100.0K
YoY Change
Total Long-Term Liabilities	$500.0K	$100.0K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.052M	$3.611M	$2.800M
Total Long-Term Liabilities	$500.0K	$100.0K	$0.00
Total Liabilities	$4.522M	$3.661M	$2.792M
YoY Change	61.96%	13.59%	-64.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$67.30M	-$48.41M	-$32.81M
YoY Change	105.14%	182.76%	291.87%
Common Stock	$112.3M	$98.68M	$97.90M
YoY Change	14.7%	166.71%	737.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$44.99M	$59.83M	$65.09M
YoY Change
Total Liabilities & Shareholders Equity	$49.51M	$63.49M	$67.89M
YoY Change	-27.06%	130.89%	510.59%

Cashflow Statement

Concept	2018 Q3	2017 Q4	2017 Q3
OPERATING ACTIVITIES
Net Income	-$7.518M	-$15.60M	-$6.940M
YoY Change	8.33%	78.34%	271.12%
Depreciation, Depletion And Amortization	$200.0K	$0.00	$0.00
YoY Change
Cash From Operating Activities	-$3.800M	-$5.170M	-$4.770M
YoY Change	-20.34%	128.76%	736.84%
INVESTING ACTIVITIES
Capital Expenditures	-$1.150M	-$400.0K	-$20.00K
YoY Change	5650.0%
Acquisitions
YoY Change
Other Investing Activities	$11.50M	$7.830M	-$15.85M
YoY Change	-172.56%
Cash From Investing Activities	$10.35M	$7.440M	-$15.88M
YoY Change	-165.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	70.00K
YoY Change	-100.0%	-100.0%	-99.4%
NET CHANGE
Cash From Operating Activities	-3.800M	-5.170M	-4.770M
Cash From Investing Activities	10.35M	7.440M	-15.88M
Cash From Financing Activities	0.000	0.000	70.00K
Net Change In Cash	6.550M	2.270M	-20.58M
YoY Change	-131.83%	-86.15%	-285.24%
FREE CASH FLOW
Cash From Operating Activities	-$3.800M	-$5.170M	-$4.770M
Capital Expenditures	-$1.150M	-$400.0K	-$20.00K
Free Cash Flow	-$2.650M	-$4.770M	-$4.750M
YoY Change	-44.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	us-gaap	Assets Assets	63493000	USD
CY2018Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3777000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3474000	USD
CY2018Q3	ck0001680048	Payables And Accruedexpenses Related Parties Current PayablesAndAccruedexpensesRelatedPartiesCurrent	275000	USD
CY2017Q4	ck0001680048	Payables And Accruedexpenses Related Parties Current PayablesAndAccruedexpensesRelatedPartiesCurrent	137000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4052000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	394000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	251000	USD
CY2018Q3	us-gaap	Assets Assets	49512000	USD
CY2018Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	18296000	USD
CY2017Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	34975000	USD
CY2018Q3	us-gaap	Other Short Term Investments OtherShortTermInvestments	22538000	USD
CY2017Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	26002000	USD
CY2018Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	69000	USD
CY2017Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	106000	USD
CY2018Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	872000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	278000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	41825000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	61361000	USD
CY2018Q3	ck0001680048	Property Plant And Equipment Excluding Assets Under Construction PropertyPlantAndEquipmentExcludingAssetsUnderConstruction	6760000	USD
CY2017Q4	ck0001680048	Property Plant And Equipment Excluding Assets Under Construction PropertyPlantAndEquipmentExcludingAssetsUnderConstruction	140000	USD
CY2018Q3	ck0001680048	Construction In Process Net ConstructionInProcessNet	33000	USD
CY2017Q4	ck0001680048	Construction In Process Net ConstructionInProcessNet	1241000	USD
CY2018Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	500000	USD
CY2017Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	500000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3611000	USD
	us-gaap	Operating Expenses OperatingExpenses	16056000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7656000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7084000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19323000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16056000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-7518000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-6940000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18892000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15687000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.70
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8293000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	7656000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	7084000	USD
	us-gaap	Operating Expenses OperatingExpenses	19373000	USD
CY2018Q3	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	470000	USD
CY2017Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	50000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	4522000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	3661000	USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2018Q3	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	0	USD
CY2017Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	9558000	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	112287000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	98679000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67300000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48408000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	44990000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	59832000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49512000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63493000	USD
CY2018Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	USD
CY2017Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	50000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	USD
CY2018Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5316000	USD
CY2017Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2188000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	13165000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5388000	USD
CY2018Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1000000	USD
CY2017Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	300000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1075000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2375000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1340000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4596000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5133000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2375000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4139000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36485000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	320000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	50296000	USD
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27146721	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26186924	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26871505	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24936626	shares
	ck0001680048	Stock Issued During Period Value Issued For Founders Agreement StockIssuedDuringPeriodValueIssuedForFoundersAgreement	0	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3869000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	3000000	shares
CY2018Q3	us-gaap	Share Based Compensation ShareBasedCompensation	903000	USD
CY2017Q3	us-gaap	Share Based Compensation ShareBasedCompensation	834000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3869000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1230000	USD
	ck0001680048	Share Issued During Period Valueon Exercise Of Warrants ShareIssuedDuringPeriodValueonExerciseOfWarrants	181000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	1075000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	2375000	USD
	ck0001680048	Issuance Of Common Stock Founder Agreement Expenses IssuanceOfCommonStockFounderAgreementExpenses	0	USD
	ck0001680048	Issuance Of Common Stock Founder Agreement Expenses IssuanceOfCommonStockFounderAgreementExpenses	1234000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	737000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	414000	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	1000	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	35000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1137000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1923000	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	138000	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-56000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-413000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-420000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12721000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7781000	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	47500000	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	34088000	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	51002000	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1075000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	181000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	181000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	49976000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16679000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5710000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35475000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27499000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18796000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33209000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Stock Issued1 StockIssued1	9558000	USD
	us-gaap	Stock Issued1 StockIssued1	4396000	USD
	ck0001680048	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	413000	USD
	ck0001680048	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	1682000	USD
	us-gaap	Depreciation Depreciation	320000	USD
	us-gaap	Depreciation Depreciation	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	125000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	117000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6566000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7115000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1383000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	322000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6793000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1381000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	5000000	shares
CY2018Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	50000	USD
CY2017Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	USD
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26263631	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25236255	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26263631	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25236255	shares
CY2018Q3	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	0	shares
CY2017Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	834756	shares
CY2018Q3	us-gaap	Interest Income Other InterestIncomeOther	138000	USD
CY2017Q3	us-gaap	Interest Income Other InterestIncomeOther	144000	USD
	us-gaap	Interest Income Other InterestIncomeOther	431000	USD
	us-gaap	Interest Income Other InterestIncomeOther	369000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2062000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	50000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5674000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.52in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s unaudited condensed financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Due to the uncertainty inherent in such estimates actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q3	us-gaap	Depreciation Depreciation	200000	USD
CY2017Q3	us-gaap	Depreciation Depreciation	0	USD
CY2018Q3	ck0001680048	Annual Fees Expenses On Founders Agreement AnnualFeesExpensesOnFoundersAgreement	100000	USD
	ck0001680048	Annual Fees Expenses On Founders Agreement AnnualFeesExpensesOnFoundersAgreement	400000	USD
CY2017Q3	ck0001680048	Annual Fees Expenses On Founders Agreement AnnualFeesExpensesOnFoundersAgreement	100000	USD
	ck0001680048	Annual Fees Expenses On Founders Agreement AnnualFeesExpensesOnFoundersAgreement	400000	USD
	ck0001680048	Potentially Dilutive Securities PotentiallyDilutiveSecurities	7647873	shares
CY2018Q3	ck0001680048	Maximum Value Of Shares Authorized MaximumValueOfSharesAuthorized	75000000	USD
CY2018Q3	ck0001680048	Commission Rate Percentage CommissionRatePercentage	0.030	pure
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	230000	shares
	ck0001680048	Potentially Dilutive Securities PotentiallyDilutiveSecurities	7039109	shares
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	MUSTANG BIO, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001680048
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Small Business EntitySmallBusiness	false
CY2018Q3	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	13500000	USD

Files In Submission

Name	View Source	Status
0001144204-18-059357-index-headers.html	Edgar Link	pending
0001144204-18-059357-index.html	Edgar Link	pending
0001144204-18-059357.txt	Edgar Link	pending
0001144204-18-059357-xbrl.zip	Edgar Link	pending
ck0001680048-20180930.xml	Edgar Link	completed
ck0001680048-20180930.xsd	Edgar Link	pending
ck0001680048-20180930_cal.xml	Edgar Link	unprocessable
ck0001680048-20180930_def.xml	Edgar Link	unprocessable
ck0001680048-20180930_lab.xml	Edgar Link	unprocessable
ck0001680048-20180930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv505897_10q.htm	Edgar Link	pending
tv505897_ex10-1.htm	Edgar Link	pending
tv505897_ex31-1.htm	Edgar Link	pending
tv505897_ex31-2.htm	Edgar Link	pending
tv505897_ex32-1.htm	Edgar Link	pending
tv505897_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MBIO
MUSTANG BIO, INC. Stock $mbio

2018 Q3 Form 10-Q Financial Statement

#000114420418059357 Filed on November 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBIO MUSTANG BIO, INC. Stock $mbio

2018 Q3 Form 10-Q Financial Statement

#000114420418059357 Filed on November 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBIO
MUSTANG BIO, INC. Stock $mbio